To Assess the Impact of the Enhanced Recovery After Surgery (ERAS) Consensus on the Effectiveness and Prognosis of Patients With Endoscopic Pituitary Tumor Surgery
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Enhanced Recovery After Surgery
- Sponsor
- Chang Gung Memorial Hospital
- Enrollment
- 70
- Locations
- 1
- Primary Endpoint
- Postoperative pain assessment
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
The goal of this observational study is to evaluate the effectiveness and impact of Enhanced Recovery After Surgery (ERAS) on patients with pituitary gland tumors.
Detailed Description
The goal of this observational study is to evaluate the effectiveness and impact of Enhanced Recovery After Surgery (ERAS) on patients with pituitary gland tumors. This study is particularly significant as ERAS has been a prominent focus in international medical treatment, emphasizing improved patient recovery and safety. The main questions it aims to answer are: How does ERAS affect the effectiveness and prognosis of patients with pituitary gland tumors? Which specific inspection and evaluation items within the ERAS protocol genuinely assist patients? Participants in this study will undergo various ERAS protocols, including pre-operative to post-operative rehabilitation measures, pain management, surgical techniques, and early resumption of eating and activities. This comprehensive approach is designed to reduce complications, shorten hospital stays, and speed up patient recovery. Additionally, this study will conduct a thorough statistical analysis to determine which aspects of the ERAS protocol are most beneficial. By comparing the outcomes of patients undergoing the ERAS protocol with those who do not, researchers aim to understand better the balance between ERAS and the Choosing Wisely initiative, which advocates for reducing unnecessary medical interventions. This research is crucial in advancing medical knowledge and practice, particularly in managing pituitary gland tumors, and contributes to the broader goals of enhancing medical quality and patient safety.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Clinical diagnosis of pituitary tumors
- •To sign a written informed consent form
Exclusion Criteria
- •Diagnosed with other malignant tumors
- •Severe infections, such as osteomyelitis, acute inflammation at the affected site, or open wounds at the treatment area
- •Pregnant women
- •Coagulation disorders or those taking anticoagulant medication
- •Other central nervous system disorders, alcohol addiction, other addictive drugs, or mental illness that may affect clinical assessment
- •Deemed unsuitable for surgical treatment or unable to comply with clinical evaluation upon assessment
Outcomes
Primary Outcomes
Postoperative pain assessment
Time Frame: During the hospitalization period, up to 24 weeks
describe postoperative Visual analogue scale (VAS) for pain assessment; the minimum value is 0 (no pain) and maximum value is 10 (most pain)
Postoperative vomiting assessment
Time Frame: During the postoperative period, up to 7 days
describe postoperative vomiting status; 0=no; 1=mild, 2=moderate, 3=severe
Length of hospital stay
Time Frame: The duration from the day of admission to the day of discharge, which is associated with this surgical procedure, assessment up to 12 weeks.
days of hospitalization related to this surgery.
Surgical complications
Time Frame: three months after operation
any complications associated with this operation
Postoperative nausea assessment
Time Frame: During the postoperative period, up to 7 days
describe postoperative nausea status; 0=no; 1=mild, 2=moderate, 3=severe
Reoperation during hospitalization
Time Frame: During the hospitalization period, the time from the first surgery to the reoperation is related to this surgical procedure, assessment up to 12 weeks.
Reoperation during hospitalization related to this surgery.
Readmission within 30 days
Time Frame: within 30 days related to this surgery.
Readmission within 30 days related to this surgery.
Secondary Outcomes
- Psychological stress- QoR-40(through study completion, an average of 1 year)
- Quality of life: WHOQOL-BREF(through study completion, an average of 1 year)
- Psychological stress- BDI-II(through study completion, an average of 1 year)
- Quality of life: Short Form-36(through study completion, an average of 1 year)
- ERAS Patient Satisfaction Questionnaire(through study completion, an average of 1 year)